CEVIMELINE Drug Patent Profile
✉ Email this page to a colleague
When do Cevimeline patents expire, and when can generic versions of Cevimeline launch?
Cevimeline is a drug marketed by Apotex Inc, Aurobindo Pharma, Bionpharma, Hikma, Novel Labs Inc, Rising, and Rubicon. and is included in seven NDAs.
The generic ingredient in CEVIMELINE is cevimeline hydrochloride. There are four drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the cevimeline hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cevimeline
A generic version of CEVIMELINE was approved as cevimeline hydrochloride by HIKMA on July 8th, 2013.
Summary for CEVIMELINE
US Patents: | 0 |
Applicants: | 7 |
NDAs: | 7 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for CEVIMELINE |
What excipients (inactive ingredients) are in CEVIMELINE? | CEVIMELINE excipients list |
DailyMed Link: | CEVIMELINE at DailyMed |
Recent Clinical Trials for CEVIMELINE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
China Medical University Hospital | Phase 4 |
Roxane Laboratories | Early Phase 1 |
University of Kentucky | N/A |